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Biliary tract cancers are aggressive malignancies that include gallbladder cancer and tumors of intra- and extrahepatic ducts and
have a poor prognosis. Surgical resection remains themain curative therapy.Nevertheless, numerous patients experience recurrence
even after radical surgery. This scenario drives the research to identify biliary tract cancer biomarkers despite the limited progress
that has been made. Recently, a large number of studies have demonstrated that deregulated expression of microRNAs is closely
associated with cancer development and progression. In this review, we highlight the role and importance of microRNAs in biliary
tract cancers with an emphasis on utilizing circulating microRNAs as potential biomarkers. Additionally, we report several single-
nucleotide polymorphisms inmicroRNA genes that are associated with the susceptibility of biliary tract tumors.
1. Background
Despite their relatively rare incidence, biliary tract cancers
(BTCs) are an aggressive tumor group with poor prognosis
and are characterized by early lymph node and systemic
metastases [1]. These tumors include gallbladder cancer
(GBC) and cholangiocarcinoma (CCA), which is divided into
intrahepatic cholangiocarcinoma (iCCA) and extrahepatic
cholangiocarcinoma (eCCA). Currently, surgical resection
remains the only curative treatment for BTCs, and neoadju-
vant chemoradiotherapy is not a standard option for patients
with these malignancies. Moreover, many cases present with
recurrence even after radical surgery, and patients with
recurrent or metastatic BTCs usually have a poor outcome
[2]. Therefore, there is a need for additional investigations to
determine potential biomarkers of BTCs for early diagnosis,
determining patient prognosis and the development of tar-
geted therapy.
Recent studies have described microRNAs (miRNAs) as
potential biomarkers in different cancer types [3–6]. How-
ever, miRNA expression and their implications in the diag-
nosis of, prognosis of, and therapeutic applications towards
BTCs remain elusive.
miRNAs are small noncoding RNAs (18–25 nucleotides)
that play important roles in the regulation of a large number
of essential biological functions that are critical to the devel-
opment of different cancer types, including cell proliferation,
differentiation, apoptosis, migration, and invasion [7].
miRNA biogenesis initiates in the nucleus, where miRNA
genes are usually transcribed by RNA polymerase II, result-
ing in a primary transcript of miRNA (pri-miRNAs) [8].
During the initial processing of pri-miRNAs, the Drosha-
DGCR8 complex cleaves the pri-miRNA, releasing a hairpin
structure named pre-miRNA (∼70 nucleotides). Pre-miRNAs
are transferred to the cytoplasm and converted into an
miRNA duplex by Exportin-5 and the Dicer-TRBP complex,
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respectively. Then, a helicase separates the double-stranded
miRNA to produce one stable single-stranded miRNA, while
the other strand is processed for autolytic degradation.
The stable mature miRNA strand is loaded into the RNA-
induced silencing complex (RISC) to mechanistically target
the 3󸀠 untranslated regions (3󸀠UTRs) of protein coding
mRNAs, thereby acting as posttranscriptional regulators by
two mechanisms: mRNA degradation (when the sequences
are perfect complements) and inhibition of translational
initiation (when there is partial complementarily) [9]. Thus,
miRNAs act as negative regulators of posttranscriptional gene
expression of target mRNAs.
It has been well established that miRNAs could regu-
late approximately 60% of human genes, including many
oncogenes and tumor suppressor genes; this phenomenon
strengthens the importance of these noncoding RNAs as
relevant regulators in cancer [10].
In this review, we focus on the roles and importance of
miRNAs in BTCs and highlight the potential of circulating
miRNAs as diagnostic and prognostic biomarkers.Therefore,
we reported several single-nucleotide polymorphisms (SNPs)
inmiRNA genes associated with BTC susceptibility.
2. Roles and Clinical Significance of
miRNAs in BTCs
A large number of deregulated miRNAs have been catego-
rized as oncomiRs (oncogene miRNAs) and/or tsmiRs (tu-
mor suppressor miRNAs) in cancer depending on the effect
of the target mRNA.
In BTCs, several studies on miRNA expression have
identified many upregulated oncomiRs and downregulated
tsmiRs as well as their potential targets (Table 1).
One of the best-described miRNAs in BTCs is hsa-miR-
21, which is usually identified as an oncomiR since its over-
expression has been associated with invasion and metastasis
[11–19, 21–25, 27, 30, 41, 47–50]. Liu et al. [13] observed
that overexpression of hsa-miR-21 significantly promotes cell
migration, invasion, and xenograft growth after transfection
of hsa-miR-21 into CCA cell lines (QBC939 and RBE). More-
over, these authors showed decreased E-cadherin expression
and increased N-cadherin and vimentin expression after
hsa-miR-21 overexpression. Thus, hsa-miR-21 could induce
the epithelial-mesenchymal transition (EMT) in CCA. In
this process, epithelial cells lose their cell polarity and
cell adhesion—probably due to the decrease of E-cadherin
expression—which allows cells to migrate and invade sur-
rounding tissues; this the loss of E-cadherin expression plays
a key role in tumor invasion and metastasis.
Similarly, aberrant expression of miRNAs also induces
EMT and enhances the metastatic potential of GBC cells [24,
51]. Bao et al. [51] reported that hsa-miR-101 overexpression
inhibits the proliferation, migration, and invasion of GBC
cells, induces the increased expression of E-cadherin and
𝛽-catenin, and causes decreased expression of vimentin.
Furthermore, these authors observed that hsa-miR-101 down-
regulation was correlated with tumor size, invasion, lymph
node metastasis, TNM stage, and poor survival in GBC
patients.These results indicate that hsa-miR-101 plays a tsmiR
role and attenuates EMT and metastasis in GBC.
Accumulating evidence has indicated that hsa-miR-146b-
5p presents critical tumor suppressor properties [52, 53]. Its
expression was significantly downregulated in GBC tissue
compared with adjacent nonneoplastic tissues. In addition,
the overexpression of hsa-miR-146b-5p in the SGC-996 GBC
cell line inhibited cell growth by enhancing apoptosis and
arresting the cells at G1 phase. However, the enforced expres-
sion of EGFR, a cell surface protein that binds to epidermal
growth factor (which inducing cell proliferation), reversed
the ability of hsa-miR-146b-5p to inhibit proliferation. More-
over, hsa-miR-146b-5p expression levels were significantly
correlated with tumor size and cancer progression [46].
Recent studies have described hsa-miR-135a-5p as having
a tsmiR role [54–56]. In GBC, Zhou et al. [44] found that
hsa-miR-135a-5p levels were significantly downregulated in
tumors compared to adjacent nontumor gallbladder tissues
and were correlated with neoplasms of histological grades
III and IV. Additionally, this study identified VLDLR as a
direct and functional target gene of hsa-miR-135a-5p in GBC
tissues. Furthermore, the transfection with a hsa-miR-135a-
5p mimetic inhibited the proliferative and colony-forming
abilities of GBC cells by arresting the cells in G1/S phase.
These data suggest that hsa-miR-135a-5p may inhibit the
proliferation of GBC cells.
3. Circulating miRNAs as Potential
BTCs Biomarkers
Several studies have reported that detectable miRNAs in
bodily fluids (e.g., plasma, serum, urine, and saliva) are more
stable in comparison with other circulating nucleic acids
[57]. Therefore, circulating miRNAs may be noninvasive and
specific diagnostic and/or prognostic molecular biomarkers
for human diseases, including cancer [4, 7, 58, 59]. In BTCs,
many circulating miRNAs seem to be reproducible and
reliable potential biomarkers as well as possible therapeutic
targets [60]. Table 2 summarizes the circulatingmiRNAswith
potential diagnostic, prognostic, and predictive biomarker
applications in BTCs.
In CCA patients, Cheng et al. [64] observed differ-
ent expression levels of circulating hsa-miR-106a not only
between CCAs and healthy controls but also among CCAs
and benign bile duct diseases (e.g., primary bile duct stone
and congenital biliary duct cysts). Furthermore, they iden-
tified decreased hsa-miR-106a levels in patients with lymph
node metastasis compared with those without metastasis,
indicating the possible role of hsa-miR-106a in the occurrence
of lymph node metastasis.
Interestingly, Voigtla¨nder et al. [65] found a distinct
circulatingmiRNAprofile in the bile and serum samples from
CCA patients and patients with primary sclerosing cholangi-
tis (PSC), a noncancerous disease. Furthermore, bile samples
from patients with concomitant PSC and CCA (PSC/CCA)
were also included in this study. Their results showed higher
expression levels of hsa-miR-126, hsa-miR-26a, hsa-miR-30b,
hsa-miR-122, and hsa-miR-1281 in PSC patients than those
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Table 1: Deregulated miRNAs in BTCs.
miRNA Tumor Expression Target Roles in BTCs Reference
hsa-miR-21 CCA
↑ PTEN
Invasion
Migration
Chemoresistance
[11–14]
↓ TPM1 DNAmethylationHistone deacetylation [15]
↓
15-PGDH Inflammation [16]
HPGD
↑ PDCD4 Lymph node metastasisMigration [17–20]
↑ RECK MigrationMetastasis [21, 22]
↑ TIMP3 Apoptosis [18]
↑ — pTNMPrognosis [23]
hsa-miR-20a GBC ↑ SMAD7
Invasion
Metastasis
Migration
Prognosis
[24]
hsa-miR-34a
CCA ↓ C-MYC Progression [25]
GBC ↓ PNUTS ProliferationPrognosis [26]
hsa-miR-335 GBC ↓ BMI1
Invasion
Lymph node metastasis
pTNM
Prognosis
[27, 28]
hsa-miR-148a CCA ↓ DNMT1 Prognosis [29]
hsa-miR-31 CCA ↑ RASA1 ApoptosisProliferation [30]
hsa-miR-200b/c CCA ↓ SUZ12
Chemoresistance
Invasion
Migration
[28]
hsa-miR-210 CCA ↑ MNT Progression [25]
Let-7a CCA ↓ RAS Progression [21]
hsa-miR-370 CCA ↓ MAP3K8 InflammationpTNM [31]
hsa-miR-29b CCA ↓ C-MYC Apoptosis [32]
hsa-miR-101 CCA ↓ VEGF Angiogenesis [33]
COX-2
hsa-miR-200b/c CCA ↓ ROCK2 Migration [28]
hsa-miR-138 CCA ↓ RHOC Migration [34]
hsa-miR-376c CCA ↓ GRB2 Migration [35]
hsa-miR-124 CCA ↓ SMYD3 Migration [36]
hsa-miR-204 CCA ↓ SLUG Migration [37]
hsa-miR-214 CCA ↓ TWIST Migration [38]
hsa-miR-200c CCA ↓ NCAM1 Migration [39]
hsa-miR-200b CCA ↑ PTPN12 Chemoresistance [14]
hsa-miR-29b CCA ↓ PIK3R1 Chemoresistance
[40]
MMP2
hsa-miR-205 CCA ↓ — Chemoresistance
hsa-miR-221 CCA ↓ PIK3R1 Chemoresistance
hsa-miR-182 GBC ↑ CADM1
Invasion
Migration
Metastasis
[27]
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Table 1: Continued.
miRNA Tumor Expression Target Roles in BTCs Reference
hsa-miR-155 GBC ↑ SMAD7
Invasion
Lymph node metastasis
Proliferation
Prognosis
[41]
hsa-miR-130a GBC ↓ HOTAIR InvasionProliferation [42]
hsa-miR-26a GBC ↓ HMGA2 pTNMProliferation [43]
hsa-miR-135a-5p GBC ↓ VLDLR pTNMProliferation [44]
hsa-miR-218-5p GBC ↓ BMI1
Invasion
Migration
Proliferation
[45]
hsa-miR-146-5p GBC ↓ EGFR
Apoptosis
pTNM
Proliferation
[46]
hsa-miR-1 GBC
↓
VEGF-A
Apoptosis
Proliferation
[47]
AXL
hsa-miR-145 GBC AXL
hsa-miR-143 GBC ↓ AXL Lymph node metastasispTNM stagehsa-miR-122
hsa-miR-187 GBC ↑
in CCA patients. However, bile samples showed hsa-miR-
640, hsa-miR-1537, andhsa-miR-3189 downregulation, aswell
as hsa-miR-412 upregulation in PSC and PSC/CCA patients.
These results demonstrated that PSC and CCA patients have
distinct miRNA profiles in their bile and serum, which could
be used to discriminate these diseases.
A small number of studies have described circulating
miRNAs in patients with GBC. Kishimoto et al. [62] demon-
strated an increase in the hsa-miR-21 expression levels in
plasma from GBC patients before curative resection when
compared with postsurgical patients and healthy volunteers.
These findings suggest that hsa-miR-21 plasma levels were
significantly affected by cancer occurrence and might have
the potential to be a diagnostic biomarker for GBC patients.
Recently, Li and Pu [47] described significantly dereg-
ulated miRNAs in the peripheral blood samples of GBC
patients compared with healthy volunteers. The expression
levels of hsa-miR-187, hsa-miR-192, and hsa-miR-202 were
upregulated while hsa-miR-143 was downregulated. These
results were associated with lymph node metastasis, inflam-
mation, immune reaction, and poor prognosis and could
be translated to clinical practice as biomarkers for the early
diagnosis, prognosis, and predictive response in patients with
GBC.
Although most studies involving circulating miRNAs
utilize real-time PCR for detection, Kojima et al. [68] used
a highly sensitive microarray denoted as “3D Gene” that
was capable of simultaneously analyzing more than 2,500
miRNAs in serum samples from patients with pancreato-
biliary cancers. These authors found several significantly
dysregulated miRNAs, including 30 upregulated miRNAs
and 36 downregulated miRNAs in BTCs. However, none of
these miRNAs could be used as single biomarker for this
type of cancer. The best results were achieved with a panel
of eight miRNAs (hsa-miR-6075, hsa-miR-4294, hsa-miR-
6880-5p, hsa-miR-6799-5p, hsa-miR-125a-3p, hsa-miR-4530,
hsa-miR-6836-3p, and hsa-miR-4476).
4. miRNA Single-Nucleotide
Polymorphisms in BTCs
In general, aberrations in miRNA expression result from
either epigenetic modifications or genomic changes, which
include chromosomal rearrangements, mutations, or SNPs
[69].
Several SNPs in miRNAs can lead to distinctions in the
miRNA expression levels, which canmodulatemiRNA-target
gene expression and, subsequently, affect cancer susceptibility
[4, 70]. However, few studies have been performed to identify
SNPs in miRNAs in BTCs patients until now.
The SNPs hsa-miR-27a rs895819, hsa-miR-570 rs4143815,
and hsa-miR-181a rs12537 have been found to play important
roles in many cancer types [71–78], and their contribution
in BTCs has been explored. Gupta et al. [70] observed
that the combination of hsa-miR-27a rs895819, hsa-miR-
570 rs4143815, and hsa-miR-181a rs12537 was the best gene-
gene interaction model for predicting the susceptibility and
treatment response inGBC patients.Moreover, the SNPs hsa-
miR-27a rs895819 and hsa-miR-181a rs12537 were associated
with treatment toxicity but had no influence on the survival
outcomes of GBC patients with locally advanced and/or
metastatic tumors.
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Table 2: Circulating miRNAs in patients with BTC as potential diagnostic, prognostic, and predictive biomarkers.
miRNA Expression Samples N samples Potentialbiomarker Method Clinical implication Reference
hsa-miR-9 ↑ Bile BTCs (9)HV (9)
Diagnostic
Prognostic RT-PCR Metastasis [61]
hsa-miR-145 ↑ Bile BTCs (9)HV (9) Diagnostic RT-PCR — [61]
hsa-miR-21 ↑
Plasma
BTCs (94)
HV (50)
BBD (2)
Diagnostic qRT-PCR Inflammatory reaction [62]
Peripheral blood GBC (40)HV (40) Diagnostic qRT-PCR — [47]
hsa-miR-150 ↑ Plasma iCCA (15) Diagnostic qRT-PCR Tumor progression [63]
hsa-miR-106a ↓ Serum CCA (103) Prognostic qRT-PCR Lymph node metastasis [64]
HV (20)
hsa-miR-126 ↑ Serum
PSC (40)
CCA (31)
HV (12)
Diagnostic RT-PCR — [65]
hsa-miR-26a ↑ Serum
PSC (40)
CCA (31)
HV (12)
Diagnostic RT-PCR — [65]
hsa-miR-30b ↑ Serum
PSC (40)
CC (31)
HV (12)
Diagnostic RT-PCR — [65]
hsa- miR-122 ↑ Serum
PSC (40)
CC (31)
HV (12)
Diagnostic RT-PCR — [65]
hsa-miR-1281 ↑ Serum
PSC (40)
CC (31)
HV (12)
Diagnostic RT-PCR — [65]
hsa-miR -187 ↑ Peripheral blood GBC (40)HV (40)
Diagnostic
Prognostic
Predictive
qRT-PCR Lymph node metastasisPoor prognosis [47]
hsa-miR-192 ↑
Peripheral blood GBC (40)HV (40)
Diagnostic
Prognostic
Predictive
qRT-PCR
Inflammatory reaction
Immune reaction
Lymph node metastasis
[47]
Serum iCCA (11)HV (09)
Diagnostic
Prognostic
miRNA
RT-PCR array
Lymph node metastasis
Poor prognosis [66]
hsa-miR-194 ↑ Serum CCA (70)HV (70) Diagnostic qRT-PCR Tumor progression [58]
hsa-miR -202 ↑ Peripheral blood GBC (40)HV (40)
Diagnostic
Prognostic
Predictive
qRT-PCR Lymph node metastasis [47]
hsa-let- 7a ↓ Peripheral blood GBC (40)HV (40) Diagnostic qRT-PCR — [47]
hsa-miR -143 ↓ Peripheral blood GBC (40)HV (40)
Diagnostic
Prognostic
Predictive
qRT-PCR
Inflammatory and
immune reaction
Lymph node metastasis
[47]
hsa-miR-335 ↓ Peripheral blood GBC (40)HV (40) Diagnostic qRT-PCR — [47]
hsa-miR-1307-3p ↓ Plasma iCCA (13)HV (5) Diagnostic qRT-PCR — [67]
hsa-miR-1275 ↑ Plasma iCCA (13)HV (5) Diagnostic qRT-PCR — [67]
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Table 2: Continued.
miRNA Expression Samples N samples Potentialbiomarker Method Clinical implication Reference
hsa- miR-320b ↑ Plasma iCCA (13)HVs (5) Diagnostic qRT-PCR — [67]
hsa-miR-874 ↑ Plasma iCCA (13)HVs (5) Diagnostic qRT-PCR — [67]
hsa-miR-483-5p ↑
Plasma iCCA (13)HV (5) Diagnostic qRT-PCR — [67]
Serum CCA (70)HV (70) Diagnostic qRT-PCR Tumor progression [58]
hsa-miR-885-5p ↑ Plasma iCCA (13)HV (5) Diagnostic qRT-PCR — [67]
hsa-miR-92b-3p ↑ Plasma iCCA (13)HV (5) Diagnostic qRT-PCR — [67]
hsa-miR-505-3p ↑ Plasma iCCA (13)HV (5) Diagnostic qRT-PCR — [67]
hsa-miR-6836-3p ↑ Serum BTCs (98)HV (150) Diagnostic 3D-Gene — [68]
hsa-miR-6075 ↑ Serum BTCs (98)HV (150) Diagnostic 3D-Gene — [68]
hsa- miR-4634 ↑ Serum BTCs (98)HV (150) Diagnostic 3D-Gene — [68]
hsa-miR-4294 ↓ Serum BTCs (98)HV (150) Diagnostic 3D-Gene — [68]
hsa-miR-6880-5p ↓ Serum BTCs (98)HV (150) Diagnostic 3D-Gene — [68]
hsa-miR-6799-5p ↓ Serum BTCs (98)HV (150) Diagnostic 3D-Gene — [68]
hsa-miR-125a-3p, ↓ Serum BTCs (98)HV (150) Diagnostic 3D-Gene Tumor progression [68]
hsa-miR-4530 ↓ Serum BTCs (98)HV (150) Diagnostic 3D-Gene — [68]
hsa-miR-7114-5p ↓ Serum BTCs (98)HV (150) Diagnostic 3D-Gene — [68]
hsa-miR-4476 ↓ Serum BTCs (98)HV (150) Diagnostic 3D-Gene — [68]
BBD: benign biliary disorders; BTCs: biliary tract cancers; CCA: cholangiocarcinoma; iCCA: intrahepatic cholangiocarcinoma; GBC: gallbladder cancer; HV:
heath volunteers; PSC: primary sclerosing cholangitis.
SNPs in pri-miRNAs and pre-miRNAs could also affect
miRNA processing, miRNA expression, and cancer sus-
ceptibility. Srivastava et al. [79] reported genetic polymor-
phisms in pre-mir-196a2 rs11614913 (C>T), pre-hsa-mir-196a
rs11614913, and pre-hsa-mir-499 rs3746444 (T>C) that were
associated with an increased overall risk of developing GBC
development. In CCA, Mihalache et al. [80] investigated the
G/Cvariant in pre-hsa-miR-146a rs2910164 and foundno sig-
nificant relationship between genetic susceptibility and CCA.
Additional studies addressing the identification of
miRNA SNPs could be useful to assess the individual suscep-
tibility of BTCs and improve our understanding of their
potential contribution to the disease as well as aid in the
development of potential clinical applications.
5. Conclusion
miRNAs are profoundly involved in tumor onset and pro-
gression [81–84]. However, the implications of miRNA for
the diagnosis, prognosis, and therapeutic options for patients
with BTCs remain unsatisfactory. This review highlighted
some miRNAs that are dysregulated in BTCs, their targets,
and the possible clinical implications. A better understanding
of the therapeutic applications of miRNAs could lead to
future clinical trials involving the inhibition of oncomiRs or
the promotion of expression of tsmiRs as new approaches
against diverse cancer types, including aggressive BTCs.
Here, we also reported several circulating miRNAs as
possible diagnostic, prognostic, and/or predictive biomarkers
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in BTCs. Circulating miRNAs could be promising potential
biomarkers for cancers because detectable miRNAs in the
bodily fluids are stable and can be measured using noninva-
sive methods [57]. BTCs are usually asymptomatic; therefore,
the use of miRNAs as early diagnostic biomarkers could be a
useful tool to improve the long-term survival of BTCpatients.
However, more studies with clinical outcomes are needed
to identify which miRNAs could serve as either a potential
therapeutic target or diagnostic and prognostic biomarkers
of BTCs.
Moreover, several SNPs in miRNAs can affect the expres-
sion of target genes, leading to a cellular disorder and, con-
sequently, tumorigenesis [4, 70]. However, few studies have
been performed to identify SNPs in the miRNAs expressed
by BTC patients until now; this review emphasizes the need
to expand the knowledge in this field of study.
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